Some users report losing 40 to 65 pounds over several months
10.1021/acs.jmedchem.5b00726 17 LiX.LuoW.TangY.WuJ.ZhangJ.ChenS.et al (2024)
BPC-157 has demonstrated healing effects in models of inflammatory bowel disease, gastric ulceration caused by non-steroidal anti-inflammatory drugs, short bowel syndrome, and intestinal fistulas
Biological Activity and Molecular Mass of Human Recombinant IGF-I LR3, ACF (A) The biological activity of Human Recombinant IGF-I LR3, ACF was tested by its ability to induce MAP/ERK signaling in transfected MCF-7 cells using a luciferase reporter assay
FIGURE 1 : Origin of bone cells
Notably, patients treated with PEG-Loxenatide accounted for the largest number in this study, but incidences of gastrointestinal adverse events (17.6% vs 30.6% to 51%) and hypoglycemia (3.1% vs 8.2% to 11.5%) were lower compared with those treated with other GLP-1RAs